Leverage biomaterials to modulate immunity for type 1 diabetes

Authors:

Abstract
The pathogeny of type 1 diabetes (T1D) is mainly provoked by the β-cell loss due to the autoimmune attack. Critically, autoreactive T cells firsthand attack β-cell in islet, that results in the deficiency of insulin in bloodstream and ultimately leads to hyperglycemia. Hence, modulating immunity to conserve residual β-cell is a desirable way to treat new-onset T1D. However, systemic immunosuppression makes patients at risk of organ damage, infection, even cancers. Biomaterials can be leveraged to achieve targeted immunomodulation, which can reduce the toxic side effects of immunosuppressants. In this review, we discuss the recent advances in harness of biomaterials to immunomodulate immunity for T1D. We investigate nanotechnology in targeting delivery of immunosuppressant, biological macromolecule for β-cell specific autoreactive T cell regulation. We also explore the biomaterials for developing vaccines and facilitate immunosuppressive cells to restore immune tolerance in pancreas.
Funding Information
  • Science, Technology and Innovation Commission of Shenzhen Municipality (JCYJ20200109142610136)
  • National Natural Science Foundation of China (31971268)
  • Basic and Applied Basic Research Foundation of Guangdong Province (2019A1515010855)
  • National Natural Science Foundation of China-Guangdong Joint Fund (2020A1515010802)
  • Basic and Applied Basic Research Foundation of Guangdong Province (2020A1515110166)
  • National Natural Science Foundation of China-Guangdong Joint Fund (No.2020A1515010802)
  • Shenzhen Science and Technology Innovation Program (Grant No. RCYX20200714114643121)
  • Shenzhen Municipal Fundamental Research Program (JCYJ20180507181654186)
  • Fundamental Research Funds for the Central Universities (19lgzd45)

This publication has 169 references indexed in Scilit: